GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Capex-to-Revenue

VGI Health Technology (XNEC:VTL) Capex-to-Revenue : 0.00 (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

VGI Health Technology's Capital Expenditure for the six months ended in . 20 was A$0.00 Mil. Its Revenue for the six months ended in . 20 was A$0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

VGI Health Technology Capex-to-Revenue Historical Data

The historical data trend for VGI Health Technology's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Capex-to-Revenue Chart

VGI Health Technology Annual Data
Trend
Capex-to-Revenue

VGI Health Technology Semi-Annual Data
Capex-to-Revenue

Competitive Comparison of VGI Health Technology's Capex-to-Revenue

For the Biotechnology subindustry, VGI Health Technology's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VGI Health Technology's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Capex-to-Revenue falls into.


VGI Health Technology Capex-to-Revenue Calculation

VGI Health Technology's Capex-to-Revenue for the fiscal year that ended in . 20 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- () /
=N/A

VGI Health Technology's Capex-to-Revenue for the quarter that ended in . 20 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- () /
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VGI Health Technology  (XNEC:VTL) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

VGI Health Technology Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Capex-to-Revenue
Comparable Companies
Traded in Other Exchanges
N/A
Address
19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003
Website
https://www.vgiht.com
VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines